Medical Company Receives Buy Rating: Price Target Maintained
$HUMA - Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target.
As an investor it's important to stay updated with major news. Get real-time stock market alerts, news, and research by creating an account here.